研究单位：[1]Sichuan Cancer Hospital and Research Institute
研究目的：
This study aimed to evaluate the efficacy and safety of first-line Toripalimab combined with bevacizumab,nab-paclitaxel and carboplatin in the treatment of patients with advanced pulmonary sarcomatoid carcinoma.
